| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99199 |
Unlisted special service, procedure or report |
446,507 |
399,185 |
$2.35M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
10,491 |
8,143 |
$782K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
6,420 |
5,416 |
$167K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
10,730 |
8,686 |
$144K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
4,441 |
3,853 |
$134K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,097 |
960 |
$98K |
| 99215 |
Prolong outpt/office vis |
324 |
301 |
$60K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
609 |
503 |
$52K |
| T1002 |
Rn services, up to 15 minutes |
2,201 |
1,512 |
$47K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
669 |
480 |
$47K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
402 |
324 |
$39K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
798 |
628 |
$39K |
| S0280 |
Medical home program, comprehensive care coordination and planning, initial plan |
811 |
707 |
$37K |
| 83655 |
|
2,472 |
2,253 |
$36K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,460 |
2,778 |
$34K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
841 |
719 |
$31K |
| 96127 |
|
5,195 |
4,175 |
$30K |
| 87428 |
|
560 |
434 |
$29K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
1,528 |
1,398 |
$26K |
| 99502 |
|
399 |
383 |
$23K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,386 |
1,089 |
$20K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,489 |
693 |
$20K |
| 99501 |
|
381 |
358 |
$19K |
| 81025 |
|
2,430 |
2,060 |
$18K |
| 99383 |
|
191 |
146 |
$15K |
| 90651 |
|
1,022 |
874 |
$13K |
| 36415 |
Collection of venous blood by venipuncture |
5,435 |
4,134 |
$13K |
| 81003 |
|
4,877 |
3,185 |
$13K |
| 85027 |
|
1,717 |
1,434 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
816 |
684 |
$11K |
| 90474 |
|
681 |
532 |
$8K |
| 90734 |
|
563 |
515 |
$7K |
| 90715 |
|
1,376 |
1,173 |
$6K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
64 |
52 |
$6K |
| 90619 |
|
1,772 |
1,404 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
38 |
31 |
$5K |
| 92551 |
|
3,023 |
2,490 |
$4K |
| 87210 |
|
1,792 |
670 |
$4K |
| 90686 |
|
2,178 |
1,814 |
$3K |
| 90716 |
|
252 |
227 |
$3K |
| 90621 |
|
293 |
227 |
$3K |
| 96160 |
|
739 |
573 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
25 |
15 |
$2K |
| 87807 |
|
151 |
131 |
$2K |
| 99173 |
|
3,194 |
2,622 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
192 |
164 |
$1K |
| 90707 |
|
210 |
187 |
$1K |
| 90674 |
|
95 |
53 |
$755.53 |
| 99406 |
|
86 |
59 |
$703.87 |
| 96161 |
|
336 |
213 |
$693.66 |
| 90633 |
|
1,323 |
1,201 |
$689.08 |
| 90480 |
|
33 |
12 |
$650.00 |
| 90661 |
|
83 |
40 |
$622.75 |
| 82950 |
|
170 |
110 |
$597.42 |
| 83020 |
|
641 |
579 |
$361.78 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
506 |
426 |
$278.71 |
| 86580 |
|
49 |
39 |
$249.94 |
| 86701 |
|
1,099 |
965 |
$121.68 |
| 80061 |
Lipid panel |
50 |
42 |
$117.56 |
| 90744 |
|
917 |
751 |
$93.32 |
| 86593 |
|
1,152 |
1,015 |
$78.94 |
| 82105 |
|
282 |
272 |
$43.44 |
| 90656 |
|
187 |
166 |
$20.53 |
| 90681 |
|
598 |
464 |
$0.00 |
| 90700 |
|
195 |
180 |
$0.00 |
| 86900 |
|
319 |
294 |
$0.00 |
| 87341 |
|
18 |
13 |
$0.00 |
| 90670 |
|
2,229 |
1,826 |
$0.00 |
| 86787 |
|
406 |
378 |
$0.00 |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
195 |
183 |
$0.00 |
| 90685 |
|
121 |
118 |
$0.00 |
| 90710 |
|
633 |
533 |
$0.00 |
| 90756 |
|
137 |
31 |
$0.00 |
| 90713 |
|
15 |
15 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
18 |
13 |
$0.00 |
| 90698 |
|
1,479 |
1,212 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
539 |
496 |
$0.00 |
| 90677 |
|
312 |
268 |
$0.00 |
| 90696 |
|
197 |
163 |
$0.00 |
| 86850 |
|
335 |
309 |
$0.00 |
| 87800 |
|
615 |
555 |
$0.00 |
| 86762 |
|
288 |
262 |
$0.00 |
| 86706 |
|
269 |
249 |
$0.00 |
| 90694 |
|
12 |
12 |
$0.00 |
| 90697 |
|
167 |
125 |
$0.00 |
| 86901 |
|
244 |
227 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
17 |
17 |
$0.00 |
| 88142 |
|
48 |
43 |
$0.00 |
| 86803 |
|
33 |
25 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
12 |
12 |
$0.00 |